NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Cedric Hermans Presenting FRONTIER2 Data on Mim8 in Adolescents and Adults with Haemophilia A
Cedric Hermans/LinkedIn
Dec 9, 2025, 09:00

Cedric Hermans Presenting FRONTIER2 Data on Mim8 in Adolescents and Adults with Haemophilia A

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

“What matters most – patient reported outcomes at ASH Cedric Hermans presenting FRONTIER2 data on Mim8 in adolescents and adults with haemophilia A (with and without inhibitors) – and it’s a reminder of what we should have been measuring all along. Not just bleeding control, but how patients actually live.

Cedric Hermans Presenting FRONTIER2 Data on Mim8 in Adolescents and Adults with Haemophilia A

The numbers:

Treatment burden – 46-62% hit clinically meaningful improvement
Joint pain – 59-95% saw relief depending on where they started
Physical activity – jumped across all groups, 100% in the on-demand cohort
Physical functioning – +4 to +17.6 on the PedsQL scale

But the real story?
88-98% of patients prefer Mim8 over what they were taking before.

Cedric Hermans Presenting FRONTIER2 Data on Mim8 in Adolescents and Adults with Haemophilia A

Three different PRO measures (Hemo-TEM, PedsQL, JPRS) all pointed the same way. Better experience, better function, less pain. And it held up over the full 52 weeks.

QW vs QM dosing showed similar PRO benefits – patients actually have flexibility that works.

When you ask patients what matters: It’s your life back. Less burden. Less pain. More activity. Those preference numbers speak for themselves”

Discover the latest in Hemostasis Today.

American Society of Hematology (ASH) ASH2025 ASH25 Cedric Hermans FRONTIER2 haemophilia Health Hematology Hemostasis Hemostasis Today Medicine Mim8 Patient Outcomes Wolfgang Miesbach
NewsFeed